Study for persistent low-level AML after initial remission
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2 trial tests a combination treatment to try to get rid of remaining cancer cells in young adults whose acute myeloid leukemia (AML) is in remission but still detectable at low levels. It may help patients eliminate “minimal residual disease” (small traces of leukemia cells) and reduce relapse risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 59 years old
- Have AML (including certain secondary or treatment-related AML) confirmed by a bone marrow test
- After initial induction chemotherapy, your leukemia must be in complete remission (or near-complete remission), but with detectable low-level disease
- Be able to do daily activities at a level described as “ECOG 0 to 2,” and be well enough for treatment
- Have certain blood counts and organ function levels near the time of randomization (enough white blood cells/ANC, platelets, and acceptable liver/kidney tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This trial tests whether the combination of venetoclax and azacitidine can clear small amounts of leukemia cells that remain after initial chemotherapy (called measurable residual disease or MRD). It is for people with acute myeloid leukemia who have MRD before a stem cell transplant.
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.